Soluble Platelet Glycoprotein V Is a Marker of Thrombosis in Patients With Ischemic Stroke by Valérie Wolff, Boris Aleil, Maurice Giroud, Jean-Louis Lorenzini,

Slides:

Advertisements

Similar presentations

Prosthetic Valve; Anticoagulation After ICH Dr.Tahsin.N.

Advertisements

Chapter 19 Agents Affecting Blood Clotting. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Blood.

Vascular Pharmacology

Cerebrovascular prevention in cardiac failure George Ntaios University of Thessaly, Larissa, Greece Lausanne 6/09/2012.

Anticoagulation? Antiplatelet? What’s the Score? COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.

Anticoagulant, Antiplatelet, and Thrombolytic Drugs

ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.

ANTIPLATELETES AGENTS BY :DR. ISRAA OMAR. The role of platelets Platelets play a critical role in thromboembolic disease like ischemic heart disease and.

Antithrombotic Therapy in Peripheral Artery Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.

Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Antiphospholipid Antibodies and Subsequent Thrombo-occlusive.

Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk by.

Omega-3 Fatty Acid Blood Levels by H. Robert Superko, Scott M. Superko, Khurram Nasir, Arthur Agatston, and Brenda C. Garrett Circulation Volume 128(19):

Erythrocyte Promotion of Platelet Reactivity Decreases the Effectiveness of Aspirin as an Antithrombotic Therapeutic Modality by Juana Valles, M. Teresa.

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.

Volume 120, Issue 4, Pages (March 2001)

From: Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation Ann Intern Med. 2007;147(8): doi: /

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

From: Risk–Benefit Profile of Long-Term Dual- Versus Single-Antiplatelet Therapy Among Patients With Ischemic StrokeA Systematic Review and Meta-analysis.

Antithrombotic Therapy in Atrial Fibrillation

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

Copyright © 2003 American Medical Association. All rights reserved.

Antithrombotic Therapy in Peripheral Artery Disease

Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei.

by J. Masjuan, M. Barón, M. Lousa, and J. M. Gobernado

Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction by Jordi Matías-Guiu, José M. Ferro, José Alvarez-Sabín,

Three-dimensional Mapping of the Initiation of Nonsustained Ventricular Tachycardia in the Human Heart by Mina K. Chung, Steven M. Pogwizd, Dave P. Miller,

by Yehuda G. Wolf, Christopher K. Zarins, Geoffrey D

Oxygen Therapy in Ischemic Stroke

Arterioscler Thromb Vasc Biol

by Jenny K. Rinehart, Rena D. Singleton, John C. Adair, Joseph R

Arterioscler Thromb Vasc Biol

Association Between Mycoplasma Pneumonia and Increased Risk of Ischemic Stroke by Chia-Hung Chiang, Chin-Chou Huang, Wan-Leong Chan, Yu-Chun Chen, Tzeng-Ji.

Treatment of Left Ventricular Assist Device Thrombosis With Extended Catheter-Directed Intraventricular Thrombolytic Therapy by Thenappan Thenappan, Allen.

Behavior and Biology: The Basic Sciences for AHA Action

by Thomas Monks, Martin Pitt, Ken Stein, and Martin James

Relative Distributions

Contribution of Stroke to the Cochrane Stroke Group Trials Register

Virtual Reality in Stroke Rehabilitation

Statin Treatment and Functional Outcome After Ischemic Stroke

Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary.

Reflux Esophagitis and the Risk of Stroke in Young Adults

by Anuj Shah, Anand Shewale, Corey J. Hayes, and Bradley C. Martin

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

The Process of Rehabilitation and Discharge Planning in Stroke

Pulse Pressure and Resistance Artery Structure in the Elderly

by Cheryl D. Bushnell, and Larry B. Goldstein

Cancer in Young Adults With Ischemic Stroke

Β2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome by H. Bas de Laat, Ronald H.W.M. Derksen,

New oral anticoagulants—what the cardiothoracic surgeon needs to know

Volume 14, Issue 4, Pages (April 2015)

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

Gregg W. Stone, MD, Herbert D. Aronow, MD, MPH Mayo Clinic Proceedings

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Volume 120, Issue 4, Pages (March 2001)

Outcomes in HeartMate II Patients With No Antiplatelet Therapy: 2-Year Results From the European TRACE Study Ivan Netuka, MD, PhD, Pierre-Yves Litzler,

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Nicolaj C. Hansson et al. JACC 2016;68:

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution Raymond G. Makhoul, M.D., Charles S. Greenberg,

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Omar Abdul-Jawad Altisent et al. JCIN 2016;9:

Jenna Barton, MSN, RN-C, PCCN

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

Soluble Platelet Glycoprotein V Is a Marker of Thrombosis in Patients With Ischemic Stroke by Valérie Wolff, Boris Aleil, Maurice Giroud, Jean-Louis Lorenzini, Nicolas Meyer, Marie-Louise Wiesel, Jean-Pierre Cazenave, and François Lanza Stroke Volume 36(3):E17-E19 March 1, 2005 Copyright © American Heart Association, Inc. All rights reserved.

Effects of antithrombotic treatment on plasma levels of sGPV in patients with ischemic stroke. Effects of antithrombotic treatment on plasma levels of sGPV in patients with ischemic stroke. Antiplatelet treatment, Aspirin or clopidogrel; ineffective anticoagulant treatment with warfarin or unfractionated heparin, INR or aPTT ratio <2; effective anticoagulant treatment, INR or aPTT ratio 2 to 3 (Kruskall–Wallis test). Valérie Wolff et al. Stroke. 2005;36:E17-E19 Copyright © American Heart Association, Inc. All rights reserved.